Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our Success

Inclusion for the 11th year in a row provides invaluable opportunity to learn from employee voices

December 3, 2025

We are extremely proud to be recognized once again as a Boston Globe Top Place to Work marking our 11th year in a row on the list. This meaningful milestone reflects the strength of our culture and the experiences that our employees create for one another every day. 

We're #4 in the "largest" companies category (1000+ employees) and are the highest ranked biotechnology company (tied with Agios Pharmaceuticals who ranks #4 in the "large" companies category) among all companies include this year. 

As we celebrate this achievement, we also want to acknowledge the voices behind it. In responding to the confidential survey (conducted by research firm Energage for The Boston Globe), our employees shared more than 2,000 comments providing us invaluable insight into what they feel makes Alnylam such a special place to work and what it is about our culture that continues to set us apart.

Each of us plays a part in making Alnylam a truly exceptional place to work. We all shape this culture which welcomes new ideas, encourages us to stretch and innovate, and keeps us focused on something bigger than ourselves. I’m grateful for the work we do together, and I’m energized by what’s ahead as we continue delivering breakthroughs that will shape the future of medicine.” - Melissa McLaughlin, Chief Human Resources Officer

In honor of Alnylam’s 11th year on the list, we’re highlighting 11 themes from the survey responses and comments that we found especially insightful, are proud of and which we feel fuel our success.

  1. A Mission that Matters - Employees consistently shared that contributing to the development of potentially life-changing medicines provides them with a true sense of purpose. Many said they feel proud to use their skills in service of patients around the world.
  2. Meaningful Impact - Employees appreciate being able to see tangible outcomes from their work. Comments reflected pride in advancing innovative new therapies, improving lives and helping patients get the care they need.
  3. Smart, Collaborative Colleagues - Employees repeatedly highlighted the high caliber of the colleagues they work with and frequently characterized them as "intelligent," "supportive" and "determined."
  4. A Culture of Support and Respect - Many employees shared that they feel valued, seen and supported, both professionally and personally. "Mutual respect" and a "strong sense of community" stood out as defining traits.
  5. Opportunities to Learn and Grow - Employees emphasized their appreciation for extensive opportunities to develop new skills, take on meaningful work and expand their careers.
  6. Values that Are Lived, Not Just Said - Comments pointed to the strength of our culture of ethics, integrity and doing the right thing. Employees frequently citied that they feel proud that our actions match our values.
  7. Flexibility to Do Great Work - Employees appreciated having a high degree of workplace autonomy and trust from managers and leadership needed to make decisions and be successful in their roles.
  8. Cross-Functional Partnership - Employees emphasized how much they enjoy and feel energized by collaborating with colleagues across teams and geographies and appreciation for how our culture supports and encourages collaborative ways of working.
  9. A Place to Be Yourself - Comments consistently highlighted feelings of inclusion and belonging. Employees shared that they can show up authentically to work and be accepted for who they are.
  10. Pride in Innovation - Comments reflected excitement about what makes Alnylam unique in the biopharmaceutical industry. Employees take pride in Alnylam's bold science and pioneering work in RNAi that define our strategy.
  11. A Community that Cares - Whether through everyday interactions or major company moments, employees described Alnylam as a place where people look out for one another, celebrate wins together and build meaningful connections.

 

The 2025 Top Place to Work survey was completed by more than 120,000 employees at 314 companies in Massachusetts. Participants complete an anonymous, research-backed survey assessing categories such as their company’s leadership, execution, connection, communication, management, work, pay and benefits. Read the entire Top Place to Work 2025 feature here.

We invite you to learn more about our award-winning culture and career opportunities available at Alnylam.

 

Tags

Careers & Culture, Articles, Boston Globe Top Places to Work, Our Culture, Careers, Awards, DE&I

Related Content See All News ›
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam
Careers & Culture Celebrating a Decade on The Boston Globe’s Top Place to Work List

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam
Careers & Culture Celebrating a Decade on The Boston Globe’s Top Place to Work List
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site